Alpha Tau Medical (DRTS) Stock

Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Alpha Tau Medical in July 2026.

Alpha Tau Medical Ltd is an Israel-based medical technology company engaged in the research, development, and commercialization of innovative cancer treatment technologies. The Company focuses on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a platform designed for the treatment of solid tumors through the localized delivery of alpha radiation within tumor tissue. Its technology utilizes radioactive radium-224 sources that release short-range alpha particles intended to damage and destroy cancer cells while limiting exposure to surrounding healthy tissue. The Company conducts activities related to product development, clinical studies, regulatory approval processes, and commercialization. Alpha Tau Medical Ltd serves the oncology sector and carries out its operations directly and through its subsidiary, Healthcare Capital Corp.

About This Stock

ALPHA TAU MEDICAL LTD

DRTS

Current Price

$12.50

Potential 12 Month Profit

-9.26%

Sector

Financials

Industry

Investment Holding Companies

Ticker

DRTS

Market Cap

$1.13B

Potential 12 Month Profit

-9.26%

Sector

Financials

Industry

Investment Holding Companies

Sixth Month Growth Performance

$12.50

+5.53 (79.34%)past 6 months

Stock Performance Snapshot

Strong Buy

Analyst Rating

Analysts highly recommend buying Alpha Tau Medical’s stock due to strong growth potential.

Average

Financial Health

Alpha Tau Medical is showing reasonable cash flow and book value per share for a young company.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

View more stocks by downloading the app for FREE

It only takes 60 seconds.

Discover More Opportunities

RUMBLE INC

Rumble Inc. is a video sharing platform and cloud services provider. The Company comprises two businesses: Rumble Services and Rumble Cloud. Rumble Services consists of Rumble Video, Rumble Studio, Rumble Advertising Center (RAC) and Rumble Wallet. Rumble Video is primarily enabled through its flagship product, Rumble.com, a free-to-use video sharing and livestreaming platform on which users can watch, share, like, comment and upload videos. Using Rumble Studio, creators can establish a variety of custom settings for their livestream, set up, go-live and control their livestream across multiple social platforms. Rumble Advertising Center is its proprietary advertising marketplace and network designed to facilitate transactions for advertisers seeking to access Rumble.com traffic and traffic from other publishers on the RAC network. Rumble Cloud is an infrastructure as a service (IaaS) offering consisting of a portfolio of compute, storage, security and networking offerings.

COMPASS DIVERSIFIED

Compass Diversified Holdings is engaged in owning and managing a diverse set of defensible, middle-market businesses across the branded consumer, industrial, healthcare, and critical outsourced services sectors. The Company categorizes its businesses into two separate groups: branded consumer businesses and industrial businesses. It operates through eight segments: 5.11 Acquisition Corp. (5.11), Boa Holdings Inc. (BOA), Relentless Topco, Inc. (PrimaLoft), THP Topco, Inc. (The Honey Pot Co. or THP), CBCP Products, LLC (Velocity Outdoor or Velocity), AMTAC Holdings, LLC (Arnold), FFI Compass, Inc. (Altor Solutions or Altor). 5.11 is a provider of purpose-built technical apparel and gear for law enforcement, firefighters, EMS, and military special operations as well as outdoor and adventure enthusiasts. PrimaLoft is a provider of branded, high-performance synthetic insulation and materials used primarily in consumer outerwear, and accessories.

TIPTREE INC

Tiptree is a financial services company providing insurance and other related services.

Baskets Featuring DRTS

Radiopharma Revolution: Promise Meets Market Risk

Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.

Published: 9 January 2026

Explore Basket